BioNTech

BioNTech SE is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
BioNTech stock price chart
vol.
change
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

BioNTech balance sheet

Report period2017 2018 2019 2020 2021 Q3 22
End date of the reporting period
Capitalization, €
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

BioNTech cash flows

Report period2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

BioNTech multipliers

Report period2017 2018 2019 2020 2021 Q3 22 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

BioNTech profitability

Report period2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
BioNTech assets
BioNTech cash flows
BioNTech dividends
0%

BioNTech dividend policy

The company pays dividends irregularly

BioNTech shares

TickerNameTypeNominal valueISINPrice
BNTX:USBioNTechDepositary receipt-US09075V1026$91.83
BioNTech news
23.06.2022
BioNTech has begun construction of an mRNA vaccine manufacturing plant in Kingali, Rwanda. The approximately 30,000-square-meter facility will be equipped with two BioNTainers. One will be used to produce mRNA vaccines and the other to handle the finished product. The first unit is planned to be delivered by the end of 2022. Production at the facility will s...
Source: {source} pictogram investors.biontech.de
Pictogram next
09.05.2022
BioNTech's IFRS net profit for 3 months of 2022 amounted to €3.699 billion, up 3.28 times from €1.128 billion in the previous year. Revenue increased 3.11 times to €6.375 billion from €2.048 billion a year earlier.
Source: {source} pictogram investors.biontech.de
Pictogram next
30.03.2022
The BioNTech Board of Directors has proposed a special dividend of $2 per share. The last day to purchase securities to receive the dividend is May 30, 2022. The annual dividend yield could be 1.16%.
Source: {source} pictogram investors.biontech.de
Pictogram next
30.03.2022
BioNTech's IFRS net income for 2021 was €10.293 billion, up many times over from €0.015 billion the previous year. Revenue increased 39.4 times to €18.977 billion from €0.482 billion a year earlier.
Source: {source} pictogram investors.biontech.de
Pictogram next
All BioNTech news
General information
Company nameBioNTech
Tags#coronavirus, #vaccines
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressAn der Goldgrube 12 Mainz, 55131 Germany
Websiteinvestors.biontech.de
Information disclosurewww.sec.gov